| Pomalidomide Teva |
Human |
pomalidomide |
Pomalidomide |
EMEA/H/C/006302 |
Teva GmbH |
2024/11/14
|
Authorised |
| Elahere |
Human |
mirvetuximab soravtansine |
mirvetuximab soravtansine |
EMEA/H/C/005036 |
AbbVie Deutschland GmbH & Co. KG |
2024/11/14
|
Authorised |
| Penbraya |
Human |
meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed) |
Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group B fHBP protein subfamily A;Neisseria meningitidis group B fHBP protein subfamily B |
EMEA/H/C/006165 |
Pfizer Europe MA EEIG |
2024/11/14
|
Withdrawn |
| Opuviz |
Human |
aflibercept |
aflibercept |
EMEA/H/C/006056 |
Samsung Bioepis NL B.V. |
2024/11/13
|
Authorised |
| Afqlir |
Human |
aflibercept |
aflibercept |
EMEA/H/C/006150 |
Sandoz GmbH |
2024/11/13
|
Authorised |
| Yuvanci |
Human |
macitentan;tadalafil |
macitentan;tadalafil |
EMEA/H/C/005001 |
Janssen-Cilag International NV |
2024/09/27
|
Authorised |
| Otulfi |
Human |
ustekinumab |
ustekinumab |
EMEA/H/C/006544 |
Fresenius Kabi Deutschland GmbH |
2024/09/25
|
Authorised |
| Fymskina |
Human |
ustekinumab |
ustekinumab |
EMEA/H/C/005805 |
Formycon AG |
2024/09/25
|
Authorised |
| Tuznue |
Human |
trastuzumab |
trastuzumab |
EMEA/H/C/006252 |
Prestige Biopharma Belgium |
2024/09/19
|
Authorised |
| Anzupgo |
Human |
delgocitinib |
Delgocitinib |
EMEA/H/C/006109 |
LEO Pharma A/S |
2024/09/19
|
Authorised |
| Epruvy (previously Ranibizumab Midas) |
Human |
ranibizumab |
ranibizumab |
EMEA/H/C/006528 |
Midas Pharma GmbH |
2024/09/19
|
Authorised |
| Axitinib Accord |
Human |
axitinib |
axitinib |
EMEA/H/C/006206 |
Accord Healthcare S.L.U. |
2024/09/19
|
Authorised |
| Loqtorzi |
Human |
toripalimab |
toripalimab |
EMEA/H/C/006120 |
Topalliance Biosciences Europe Limited |
2024/09/19
|
Authorised |
| Vyloy |
Human |
zolbetuximab |
zolbetuximab |
EMEA/H/C/005868 |
Astellas Pharma Europe B.V. |
2024/09/19
|
Authorised |
| Iqirvo |
Human |
elafibranor |
Elafibranor |
EMEA/H/C/006231 |
Ipsen Pharma |
2024/09/19
|
Authorised |
| Kayfanda |
Human |
odevixibat |
odevixibat sesquihydrate |
EMEA/H/C/006462 |
Ipsen Pharma |
2024/09/19
|
Authorised |
| Ituxredi |
Human |
rituximab |
rituximab |
EMEA/H/C/006224 |
Reddy Holding GmbH |
2024/09/19
|
Authorised |
| Vevizye |
Human |
ciclosporin |
ciclosporin |
EMEA/H/C/006250 |
Laboratoires Théa |
2024/09/19
|
Authorised |
| Eksunbi |
Human |
ustekinumab |
ustekinumab |
EMEA/H/C/006448 |
Samsung Bioepis NL B.V. |
2024/09/12
|
Withdrawn |
| Enzalutamide Viatris |
Human |
enzalutamide |
enzalutamide |
EMEA/H/C/006299 |
Viatris Limited |
2024/08/22
|
Authorised |